RU2005141759A - Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений - Google Patents
Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений Download PDFInfo
- Publication number
- RU2005141759A RU2005141759A RU2005141759/15A RU2005141759A RU2005141759A RU 2005141759 A RU2005141759 A RU 2005141759A RU 2005141759/15 A RU2005141759/15 A RU 2005141759/15A RU 2005141759 A RU2005141759 A RU 2005141759A RU 2005141759 A RU2005141759 A RU 2005141759A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- angiotensin
- antagonist
- cholesterol lowering
- lowering agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Electrotherapy Devices (AREA)
- Saccharide Compounds (AREA)
Claims (16)
1. Применение антагониста ангиотензина II, или его фармацевтически приемлемого производного, или фармацевтически приемлемой соли для производства лекарственного средства для профилактики или уменьшения сердечно-сосудистых явлений у пациентов с высоким риском, не имеющих признаков дисфункции левого желудочка или сердечной недостаточности, где сердечно-сосудистые явления представляют собой инсульт, сердечно-сосудистую смерть и инфаркт миокарда.
2. Применение по п.1, где пациенты имеют риск сердечно-сосудистых явлений из-за манифестировавшей ишемической болезни сердца, преходящих ишемических приступов или инсульта в анамнезе, или заболевания периферических сосудов в анамнезе.
3. Применение по п.1, где пациенты больны диабетом.
4. Применение по любому из пп.1-3, где антагонист ангиотензина II представляет собой саралазинацетат, кандесартан цилексетил, валсартан, кандесартан, лосартан калия, эпросартан, ирбесартан, тазосартан или телмисартан, или их фармацевтически приемлемые производные.
5. Применение по любому из пп.1-3, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании с другим антигипертензивным средством, понижающим содержание холестерина средством, мочегонным средством или аспирином.
6. Применение по п.5, где антигипертензивным средством является блокатор кальциевого канала или бета-блокатор.
7. Применение по любому из пп.1-3, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании со средством, понижающим содержание холестерина.
8. Применение по п.7, где средством, понижающим содержание холестерина, является статин.
9. Применение по п.8, где статином является ловастатин, правастатин, симвастатин или флювастатин.
10. Применение антагониста ангиотензина II, или его фармацевтически приемлемого производного, или фармацевтически приемлемой соли для производства лекарственного средства для профилактики или уменьшения диабета у пациентов с высоким риском, не имеющих признаков дисфункции левого желудочка или сердечной недостаточности.
11. Применение по п.10, где антагонист ангиотензина II представляет собой саралазинацетат, кандесартан цилексетил, валсартан, кандесартан, лосартан калия, эпросартан, ирбесартан, тазосартан или телмисартан, или их фармацевтически приемлемые производные.
12. Применение по п.10 или 11, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании с другим антигипертензивным средством, понижающим содержание холестерина средством, мочегонным средством или аспирином.
13. Применение по п.12, где антигипертензивным средством является блокатор кальциевого канала или бета-блокатор.
14. Применение по п.10 или 11, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании со средством, понижающим содержание холестерина.
15. Применение по п.14, где средством, понижающим содержание холестерина, является статин.
16. Применение по п.15, где статином является ловастатин, правастатин, симвастатин или флювастатин.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15143699P | 1999-08-30 | 1999-08-30 | |
US60/151.436 | 1999-08-30 | ||
US60/151,436 | 1999-08-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002107985/15A Division RU2276997C2 (ru) | 1999-08-30 | 2000-08-30 | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2005141759A true RU2005141759A (ru) | 2007-07-10 |
Family
ID=22538761
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002107985/15A RU2276997C2 (ru) | 1999-08-30 | 2000-08-30 | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
RU2005141759/15A RU2005141759A (ru) | 1999-08-30 | 2005-12-30 | Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002107985/15A RU2276997C2 (ru) | 1999-08-30 | 2000-08-30 | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
Country Status (31)
Country | Link |
---|---|
US (4) | US20040087645A1 (ru) |
EP (1) | EP1216038B1 (ru) |
JP (1) | JP4870888B2 (ru) |
KR (2) | KR20020040795A (ru) |
CN (1) | CN1268331C (ru) |
AT (1) | ATE303800T1 (ru) |
AU (3) | AU7649100A (ru) |
BG (2) | BG65474B1 (ru) |
BR (1) | BR0013704A (ru) |
CA (1) | CA2382549C (ru) |
CZ (1) | CZ300687B6 (ru) |
DE (1) | DE60022525T2 (ru) |
DK (1) | DK1216038T3 (ru) |
EE (1) | EE05670B1 (ru) |
ES (1) | ES2246894T3 (ru) |
HK (1) | HK1048267B (ru) |
HR (1) | HRP20020170A2 (ru) |
HU (1) | HUP0203326A3 (ru) |
IL (2) | IL148127A0 (ru) |
ME (1) | ME00429B (ru) |
MX (1) | MXPA02001694A (ru) |
NO (1) | NO331616B1 (ru) |
NZ (2) | NZ517468A (ru) |
PL (1) | PL353199A1 (ru) |
RS (1) | RS50377B (ru) |
RU (2) | RU2276997C2 (ru) |
SK (1) | SK2692002A3 (ru) |
TR (1) | TR200200515T2 (ru) |
UA (2) | UA77151C2 (ru) |
WO (1) | WO2001015674A2 (ru) |
ZA (1) | ZA200201470B (ru) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1498124B1 (en) * | 1997-10-17 | 2007-07-04 | Ark Therapeutics Limited | The use of inhibitors of the renin-angiotensin system |
CN101011390A (zh) * | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
RU2276997C2 (ru) * | 1999-08-30 | 2006-05-27 | Санофи-Авентис Дойчланд Гмбх | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
MXPA03001509A (es) * | 2000-08-22 | 2003-06-09 | Boehringer Ingelheim Pharma | Combinacion farmaceutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversion de la angiotensina i. |
GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
WO2002017913A1 (fr) * | 2000-08-30 | 2002-03-07 | Sankyo Company, Limited | Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque |
US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
GB0119460D0 (en) * | 2001-08-09 | 2001-10-03 | Ark Therapeutics Ltd | The use of inhibitors of the renin-angiotensin system |
US6576256B2 (en) | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
AU2002335843A1 (en) * | 2001-10-17 | 2003-04-28 | King Pharmaceuticals Research And Development, Inc | Use of ace inhibitors for reducing type 2 diabetes in high risk patients |
JP2005511631A (ja) * | 2001-11-23 | 2005-04-28 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 脳血管障害発作の急性期における高血圧症の治療 |
DE10229180A1 (de) | 2002-06-28 | 2004-01-29 | Aventis Pharma Deutschland Gmbh | Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen |
EP1382334A1 (en) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
EP1553941A1 (en) * | 2002-10-16 | 2005-07-20 | Recordati Ireland Limited | Lisinopril/lercanidipine combination therapy |
BRPI0406812A (pt) * | 2003-01-16 | 2005-12-27 | Boehringer Ingelheim Int | Combinação farmacêutica para a profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais |
DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
NZ541454A (en) * | 2003-01-31 | 2008-04-30 | Daiichi Sankyo Co Ltd | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
US7169805B2 (en) * | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
WO2005011586A2 (en) | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
WO2005030202A1 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
CA2558020A1 (en) * | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
CA2579716A1 (en) * | 2004-06-23 | 2006-01-05 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
US20060159742A1 (en) * | 2004-11-05 | 2006-07-20 | King Pharmaceutical Research & Development, Inc. | Stabilized individually coated ramipril particles, compositions and methods |
WO2006079496A1 (en) * | 2005-01-26 | 2006-08-03 | Lek Pharmaceuticals D.D. | New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance |
US20080279942A1 (en) * | 2005-06-27 | 2008-11-13 | Takeshi Hamaura | Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker |
US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
WO2007053406A1 (en) * | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
US20070185065A1 (en) * | 2006-02-03 | 2007-08-09 | Vikramjit Chhokar | Combination therapy for coronary artery disease |
BRPI0716411A2 (pt) * | 2006-08-28 | 2013-09-24 | Sanofi Aventis Deutschland | mÉtodos para o abaixamento dos nÍveis de glicose |
TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
WO2008054121A1 (en) * | 2006-10-30 | 2008-05-08 | Hanall Pharmaceutical Company. Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
CN101528204B (zh) | 2006-10-30 | 2012-12-12 | 韩诺生物制约株式会社 | 包含血管紧张素Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物 |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
NZ596064A (en) * | 2009-04-30 | 2014-03-28 | Reddy’S Lab Ltd Dr | Fixed dose drug combination formulations |
US20110160200A1 (en) * | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
WO2011071951A2 (en) * | 2009-12-07 | 2011-06-16 | Johns Hopkins University | N-acyloxysulfonamide and n-hydroxy-n-acylsulfonamide derivatives |
MX356796B (es) * | 2009-12-07 | 2018-06-14 | Cardioxyl Pharmaceuticals Inc | Derivados de hidroxilamina bis-acilados. |
MA34130B1 (fr) | 2010-02-24 | 2013-04-03 | Sanofi Aventis Deutschland | Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation |
BR112013015826A2 (pt) * | 2010-12-21 | 2016-07-12 | Silanes Sa De Cv Lab | composição estável de agentes redutores de colesterol, agentes anti-hipertensivos e agentes antiagregantes plaquetários |
BR102012020648A2 (pt) * | 2012-08-17 | 2014-12-09 | Hypermarcas S A | Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido |
KR101579656B1 (ko) * | 2013-12-12 | 2015-12-22 | 가천대학교 산학협력단 | 프라바스타틴과 발사르탄을 포함하는 약학 조성물 |
CN110833620A (zh) * | 2018-08-15 | 2020-02-25 | 王镕 | 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (ru) * | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
DE3226768A1 (de) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
US4448784A (en) * | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US4722810A (en) * | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
DE3413710A1 (de) * | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur behandlung der herzinsuffizienz |
US5684016A (en) * | 1984-04-12 | 1997-11-04 | Hoechst Aktiengesellschaft | Method of treating cardiac insufficiency |
US5231080A (en) * | 1985-10-15 | 1993-07-27 | Hoechst Aktiengesellschaft | Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease |
EP0241201A3 (en) | 1986-04-07 | 1990-05-23 | Merck & Co. Inc. | Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure |
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
DE3633496A1 (de) * | 1986-10-02 | 1988-04-14 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln |
FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
DE3704661A1 (de) * | 1987-02-14 | 1988-08-25 | Hoechst Ag | Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung |
US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
JPH0657707B2 (ja) | 1987-05-25 | 1994-08-03 | 吉富製薬株式会社 | ピペリジン化合物 |
DE3739690A1 (de) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
EP0331014A3 (de) * | 1988-03-02 | 1991-10-23 | THERA - Patent Verwaltungs-GmbH | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe |
US5217958A (en) * | 1988-03-03 | 1993-06-08 | E. R. Squibb & Sons, Inc. | 1,2-hydroxy phosphonates and derivatives thereof |
US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
DE3818245A1 (de) * | 1988-05-28 | 1989-12-07 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln |
IE940109L (en) | 1988-10-13 | 1990-04-13 | Sandoz Ag | 7-substituted-hept-6-enoic and -heptanoic acids and¹derivatives thereof |
WO1990005531A1 (en) * | 1988-11-21 | 1990-05-31 | Abbott Laboratories | Method for treating vascular diseases |
CA2016467A1 (en) | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
DE3926606A1 (de) * | 1989-08-11 | 1991-02-14 | Hoechst Ag | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie |
US5212165A (en) * | 1989-10-23 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor |
US5061694A (en) * | 1989-10-23 | 1991-10-29 | E. R. Squibb & Sons, Inc. | Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor |
CA2026686A1 (en) | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
US5223516A (en) * | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
US5140012A (en) | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
US5166143A (en) * | 1990-05-31 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing an ace inhibitor |
US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
CA2042526A1 (en) | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
CA2048699A1 (en) | 1990-09-04 | 1992-03-05 | Abraham Sudilovsky | Method for preventing or treating cerebro-vascular disease employing ceronapril |
US5470975A (en) * | 1990-10-16 | 1995-11-28 | E.R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
US5430145A (en) * | 1990-10-18 | 1995-07-04 | Merrell Dow Pharmaceuticals Inc. | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
CA2053340C (en) | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
CA2052014A1 (en) | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
US5157025A (en) | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
US5506361A (en) * | 1991-05-08 | 1996-04-09 | Theupjohn Company | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same |
GB9110635D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
US5225401A (en) * | 1991-08-12 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Treatment of congestive heart failure |
US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
ZA927211B (en) | 1991-09-27 | 1993-03-24 | Merrell Dow Pharma | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE. |
AU657793B2 (en) | 1991-09-27 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
JPH06107661A (ja) | 1991-10-24 | 1994-04-19 | Upjohn Co:The | イミダゾール誘導体およびこれを有効成分とする医薬組成物 |
US5219856A (en) * | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
US5977160A (en) * | 1992-04-10 | 1999-11-02 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
US5552397A (en) * | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
DK0640086T3 (da) * | 1992-05-15 | 1999-12-06 | Merrell Pharma Inc | Mercaptoacetylamido-pyridazo[1,2-a][1,2]diazepin-derivateranvendelige som enkephalinase- og ACE-inhibitorer |
AU675660B2 (en) * | 1992-07-17 | 1997-02-13 | Merck & Co., Inc. | Substituted biphenylmethylimidazopyridines |
US5266583A (en) * | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
US5504080A (en) * | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
GB9223860D0 (en) * | 1992-11-13 | 1993-01-06 | Glaxo Group Ltd | Chemical compounds |
DE4308504A1 (de) | 1993-03-18 | 1994-09-22 | Knoll Ag | Neue Verwendung einer Kombination aus Verapamil und Trandolapril |
DE4309553A1 (de) * | 1993-03-24 | 1994-09-29 | Bayer Ag | Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat |
CA2140553A1 (en) * | 1993-06-11 | 1994-12-22 | Hitoshi Oinuma | Amino acid derivative |
US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
US5362772A (en) * | 1993-07-09 | 1994-11-08 | E. I. Du Pont De Nemours And Company | Crosslinked microgel for cathodic electrocoating compositions |
US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
US5525723A (en) * | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
US6369103B1 (en) * | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
ES2079315B1 (es) * | 1994-02-24 | 1996-10-16 | Uriach & Cia Sa J | Nuevas imidazopiridinas. |
ES2105939B1 (es) * | 1994-08-02 | 1998-07-01 | Uriach & Cia Sa J | Nuevos pirazoles con actividad antagonista de la angiotensina ii. |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
EP0738510A3 (fr) * | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
US5656603A (en) * | 1995-05-31 | 1997-08-12 | Loyola University Of Chicago | Aminopeptidase P inhibitors and uses thereof |
EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
JPH1081633A (ja) * | 1996-07-16 | 1998-03-31 | Sankyo Co Ltd | 医薬組成物 |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
EP1498124B1 (en) * | 1997-10-17 | 2007-07-04 | Ark Therapeutics Limited | The use of inhibitors of the renin-angiotensin system |
US6403856B1 (en) * | 1998-10-19 | 2002-06-11 | Uop Llc | Process for separating alkylaromatic hydrocarbons |
DE19913528A1 (de) | 1998-12-21 | 2000-06-29 | Sanol Arznei Schwarz Gmbh | Neue Verwendung von Moexipril |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
RU2276997C2 (ru) | 1999-08-30 | 2006-05-27 | Санофи-Авентис Дойчланд Гмбх | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
US20050065203A1 (en) * | 2001-10-17 | 2005-03-24 | Salim Yusuf | Method of reducing type 2 diabetes in high risk patients |
JP2005511631A (ja) * | 2001-11-23 | 2005-04-28 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 脳血管障害発作の急性期における高血圧症の治療 |
-
2000
- 2000-08-30 RU RU2002107985/15A patent/RU2276997C2/ru not_active IP Right Cessation
- 2000-08-30 NZ NZ517468A patent/NZ517468A/en not_active IP Right Cessation
- 2000-08-30 WO PCT/EP2000/008461 patent/WO2001015674A2/en active Application Filing
- 2000-08-30 PL PL00353199A patent/PL353199A1/xx not_active Application Discontinuation
- 2000-08-30 MX MXPA02001694A patent/MXPA02001694A/es active IP Right Grant
- 2000-08-30 AT AT00965906T patent/ATE303800T1/de active
- 2000-08-30 DE DE60022525T patent/DE60022525T2/de not_active Expired - Lifetime
- 2000-08-30 KR KR1020027002626A patent/KR20020040795A/ko not_active Application Discontinuation
- 2000-08-30 SK SK269-2002A patent/SK2692002A3/sk unknown
- 2000-08-30 UA UA2002032518A patent/UA77151C2/uk unknown
- 2000-08-30 CA CA002382549A patent/CA2382549C/en not_active Expired - Fee Related
- 2000-08-30 IL IL14812700A patent/IL148127A0/xx unknown
- 2000-08-30 JP JP2001519888A patent/JP4870888B2/ja not_active Expired - Fee Related
- 2000-08-30 ME MEP-2008-643A patent/ME00429B/me unknown
- 2000-08-30 ES ES00965906T patent/ES2246894T3/es not_active Expired - Lifetime
- 2000-08-30 KR KR1020127009682A patent/KR20120055730A/ko not_active Application Discontinuation
- 2000-08-30 CN CNB008113947A patent/CN1268331C/zh not_active Expired - Fee Related
- 2000-08-30 DK DK00965906T patent/DK1216038T3/da active
- 2000-08-30 CZ CZ20020770A patent/CZ300687B6/cs not_active IP Right Cessation
- 2000-08-30 AU AU76491/00A patent/AU7649100A/en not_active Abandoned
- 2000-08-30 RS YUP-85/02A patent/RS50377B/sr unknown
- 2000-08-30 EE EEP200200086A patent/EE05670B1/xx not_active IP Right Cessation
- 2000-08-30 HU HU0203326A patent/HUP0203326A3/hu not_active Application Discontinuation
- 2000-08-30 EP EP00965906A patent/EP1216038B1/en not_active Revoked
- 2000-08-30 BR BR0013704-9A patent/BR0013704A/pt not_active Application Discontinuation
- 2000-08-30 TR TR2002/00515T patent/TR200200515T2/xx unknown
-
2002
- 2002-01-28 BG BG106360A patent/BG65474B1/bg unknown
- 2002-01-28 BG BG110003A patent/BG110003A/bg unknown
- 2002-02-12 IL IL148127A patent/IL148127A/en unknown
- 2002-02-21 ZA ZA200201470A patent/ZA200201470B/en unknown
- 2002-02-26 HR HR20020170A patent/HRP20020170A2/xx not_active Application Discontinuation
- 2002-02-27 NO NO20020978A patent/NO331616B1/no not_active IP Right Cessation
-
2003
- 2003-01-23 HK HK03100570.5A patent/HK1048267B/zh not_active IP Right Cessation
- 2003-10-28 US US10/694,001 patent/US20040087645A1/en not_active Abandoned
-
2004
- 2004-01-20 NZ NZ530702A patent/NZ530702A/en not_active IP Right Cessation
- 2004-12-02 US US11/001,028 patent/US20050101658A1/en not_active Abandoned
-
2005
- 2005-09-13 AU AU2005209687A patent/AU2005209687A1/en not_active Abandoned
- 2005-12-30 RU RU2005141759/15A patent/RU2005141759A/ru not_active Application Discontinuation
-
2006
- 2006-01-11 UA UAA200600263A patent/UA88265C2/ru unknown
- 2006-07-21 US US11/490,061 patent/US7368469B2/en not_active Expired - Lifetime
-
2008
- 2008-05-22 US US12/125,313 patent/US20080287403A1/en not_active Abandoned
-
2009
- 2009-02-25 AU AU2009200746A patent/AU2009200746B8/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005141759A (ru) | Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений | |
RU2002107985A (ru) | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений | |
JP2003527325A5 (ru) | ||
RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
IL160643A (en) | Orally administrable pharmaceutical dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor and aspirin and a packaged kit | |
RU2005128124A (ru) | Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности | |
HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
RU2006132668A (ru) | Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний | |
US20030181500A1 (en) | Medicinal compositions for the prevention or treatment of cardiac failure | |
JP2007522203A5 (ru) | ||
RU2006117790A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением | |
Lee | Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria | |
Ross et al. | Candesartan cilexetil in cardiovascular disease | |
Meredith | Candesartan cilexetil–a review of effects on cardiovascular complications in hypertension and chronic heart failure | |
JP2002535367A5 (ru) | ||
CN1750830A (zh) | 双嘧达莫与乙酰水杨酸及血管紧张素ⅱ拮抗剂的组合在预防中风中的应用 | |
CA2360691A1 (en) | Use of angiotensin ii receptor antagonists for treating acute myocardial infarction | |
Oparil et al. | Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy | |
Silverstein et al. | ARBs and target organ protection: exploring benefits beyond their antihypertensive effects | |
ZA200106022B (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction. | |
Sever | Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists | |
CA2493208A1 (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
Derosa et al. | Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination | |
KR20070111468A (ko) | 마니디핀과 스타틴의 치료용 복합물 | |
JP2005511631A (ja) | 脳血管障害発作の急性期における高血圧症の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100913 |